Bristol Myers Squibb (BMS) has shared positive top-line results from two late-stage studies of its oral TYK2 inhibitor ...

Axsome Therapeutics has announced that it has successfully completed its late-stage clinical programme evaluating ...

Step into the future of medical education with our exclusive webinar series from February 25-26, designed specifically for Pharma leaders. This transformative series will showcase the 2025 Pharma ...

AstraZeneca’s Tagrisso (osimertinib) has been approved by the European Commission (EC) to treat a new subset of lung cancer patients. The epidermal growth factor receptor (EGFR)-tyrosine kinase ...

As the world’s third largest pharmaceutical market, Japan accounted for approximately 6% of the $1.5tn in global pharmaceutical sales in 2022. While this makes it an attractive market for all ...

Pfizer’s Braftovi (encorafenib) regimen has been granted accelerated approval by the US Food and Drug Administration (FDA) to treat metastatic colorectal cancer (mCRC). The drug has been authorised ...

For many years the pharma sector has been vocal in its commitment to a ‘patient-focused’ approach. As a result, there does seem to be more attention on the patient across med affairs, marketing and ...

Is your medical education strategy reaching the right HCPs in the formats they prefer? Discover actionable insights to elevate the impact of your medical education efforts in the latest Medical ...

Polymorphic Marketing Limited is a boutique marketing agency specialising in life science, biotechnology, laboratory consumables and scientific equipment marketing.

Our aim is to provide both our clients and candidates with a focussed and supportive recruitment experience as well as offering a wealth of additional services. We are dedicated to revisiting ...

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we help life science ...

Novo Nordisk has announced an investment of 8.5 billion Danish kroner, or approximately $1.2bn, to establish a new rare disease production facility in Odense, Denmark. Construction on the new site, ...